Short answer
ACCENDRA HEALTH INC/VA/ (ACH) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Filing contains only signature and cover-page information, with no substantive Regulation FD disclosure.
ACCENDRA HEALTH INC/VA/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Filing contains only signature and cover-page information, with no substantive Regulation FD disclosure
- Report signed August 10, 2026 by Heath H. Galloway, Executive Vice President, General Counsel and Corporate Secretary
Item EX-99.1 · Exhibit EX-99.2
- Q2 revenue $613.2M, down from $681.9M; adjusted EBITDA $60.1M versus $96.6M
- Q2 adjusted loss $14.3M, or $0.19 per share, versus adjusted income $20.5M previously
- Debt reduced $385M to $1.718B, but cash fell to $7.7M and net debt remained $1.710B
- 2026 guidance: revenue $2.45B-$2.55B, adjusted EBITDA $300M-$320M, free cash flow breakeven to slightly positive
- CEO Edward Pesicka intends to retire and leave the board by year-end 2026, creating leadership-transition risk
Other items in this filing:
- Item 2.02: Results of Operations and Financial Condition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACCENDRA HEALTH INC/VA/ 8-K filings
Get the next ACH 8-K as it lands
Follow ACH for push alerts, or ask the research agent what this filing means.